GlassScriptPhysician profile
Sanjay V Vadgama
NPI 1679548556
$7,152.95
in general payments reported to CMS, 2019-2025
54 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $724 · 2021: $810 · 2022: $928 · 2023: $1,210 · 2024: $1,777 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.38 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $606.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| United Therapeutics Corporation | $566.10 | 2022-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $472.50 | 2019-2024 | (8874) Incourage |
| Astrazeneca Pharmaceuticals LP | $421.16 | 2019-2025 | Airsupra, Andexxa, Fasenra |
| Grifols USA, LLC | $387.86 | 2019-2025 | Prolastin-C Liquid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.65 | 2019-2025 | Lifevest |
| Pfizer INC. | $299.62 | 2019-2024 | |
| Insmed, INC. | $277.88 | 2023-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $265.11 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mallinckrodt Hospital Products INC. | $239.18 | 2020-2024 | Acthar |
| Mylan Specialty L.P. | $224.61 | 2019-2024 | Yupelri |
| Amgen INC. | $195.67 | 2021-2025 | Tezspire |
| Abbvie INC. | $167.67 | 2021-2023 | Teflaro, Dalvance |
| Harmony Biosciences LLC | $161.65 | 2020-2022 |
Show all 47 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Vadgama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.